Overview of This Study:
The study involved four major activities to estimate the current market size for transdermal drug delivery systems. Exhaustive secondary research was done to collect information about the market, peer markets, and the parent market.
The next step was to validate these findings, assumptions, and sizing with industry experts across value chain through primary research. Thirdly, both top-down and bottom-up approaches were employed to estimate the complete market size. Finally, the market breakdown and data triangulation was used to estimate the market size of segments and subsegments.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203190114
Secondary Research
In the secondary research process, various secondary sources such as the International Association for the Study of Pain (IASP), International Parkinson and Movement Disorder Society, World Parkinson Congress, International Planned Parenthood Federation (IPPF), International Society of Endocrinology, International Diabetes Federation, International Council of Cardiovascular Prevention and Rehabilitation (ICCPR), European Pain Federation (EFIC), European Society of Contraception and Reproductive Health (ESC), European Society of Cardiology, European Parkinson’s Disease Association (EPDA), European Association for the Study of Diabetes (EASD), Asia Pacific Council on Contraception (APCOC), Asian Pacific Society of Cardiology, ASEAN Federation of Endocrine Societies, Guttmacher Institute, National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), United Nations Department of Economic and Social Affairs, directories, industry journals, databases, press releases, and annual reports of the companies have been used to identify and collect information useful for the study of this market.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the transdermal drug delivery systems market. The primary sources from the demand side include personnel from research organizations, academic institutes, and purchase managers.
Recent Developments:
# In January 2018, Hisamitsu Pharmaceutical (Japan) launched ALLESAGA TAPE in the Japanese market.
# In July 2018, UCB (Belgium) received the Import Drug License (IDL) for its transdermal rotigotine patch—NEUPRO from the China Food and Drug Administration (CFDA).
# In August 2018, Luye Pharma (China) signed an agreement with Bayer AG (Switzerland) to acquire the global rights to the Apleek contraceptive transdermal patch
Home care settings segment is expected to grow at the fastest rate during the forecast period
On the basis of end users, the transdermal drug delivery systems market is segmented into home care settings and hospitals & clinics. The home care settings segment is expected to grow at a higher CAGR during the forecast period. The high growth in this segment can be attributed to the increase in self-administration of medication at home, rapid growth in the geriatric population across the globe, and the growing need for cost-effective drug administration.
Key Questions addressed by the report
# Which are the key players in the market and how intense is the competition?
# Emerging countries have immense opportunities for the growth of transdermal drug delivery systems market, will this scenario continue?
# Which product market will dominate in future?
# What does the future look like for transdermal drug delivery systems?
# What are the challenges hindering the adoption of transdermal drug delivery systems?
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203190114
North America is expected to hold the largest market share during the forecast period
North America is one of the major revenue generating regions in the transdermal drug delivery systems market. The transdermal drug delivery systems market in the region is driven by the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.
